Skip to content

Use of Ginger to control nausea and vomiting caused by chemotherapy in patients with cervical cancer undergoing treatment: an experiment

Use of Ginger (Zingiber Officinale) in the management of chemotherapy-induced nausea and vomiting in patients with cervical Cancer undergoing antineoplastic treatment: a randomized clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-47yx6p9
Enrollment
Unknown
Registered
2021-12-16
Start date
2021-03-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vomiting

Interventions

Experimental Group 1 (EG1): 16 women given cervical cancer treatment with Cisplatin associated with radiotherapy will receive capsules containing 250mg of the ginger extract contained in capsules, ing

Sponsors

Liga Norte Riograndense Contra o Câncer
Lead Sponsor
Liga Norte Riograndense Contra o Câncer
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Over 18 years old; have a diagnosis of cervical cancer with histological confirmation; have an indication for treatment with cisplatin 40mg/m² weekly associated with radiotherapy; preserved capsule swallowing capacity

Exclusion criteria

Exclusion criteria: Have a history of hypersensitivity to ginger; pregnancy or breastfeeding; have another primary neoplasm; ongoing chemotherapy treatment; having undergone previous antineoplastic and/or radiotherapy treatment; radiotherapy treatment in the epigastric region of the abdomen; surgery scheduled during the study period; have any feeding device (nasoenteric tube, gastrostomy, or jejunostomy); in simultaneous use of a supplement or ginger-based foods; using anticoagulants; have a history of bleeding disorders (severe thrombocytopenia), hyperthyroidism, and heart disease; a pre-existing condition causing nausea and vomiting.

Design outcomes

Primary

MeasureTime frame
Assess the reduction of nausea and vomiting using the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 scale adapted for nausea and vomiting. In this way, it is possible to measure the intensity and intensity of events.

Secondary

MeasureTime frame
To assess the quality of life of patients using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30) and EORTC quality of life cervical cancer module (EORTC QLQ Cx24). With these instruments it is expected to analyze the interference of the treatment in the quality of life, as well as the influence of ginger in its improvement.

Countries

Brazil

Contacts

Public ContactRomeika Lorena da Silva
lorena.romeika@gmail.com+55-084-999616690

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 12, 2026